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Stepping Down Asthma Treatment: How and When
Linda Rogers and Joan Reibman
Abstract
Purpose of Review—Guidelines suggest that asthma medication should be reduced once
asthma control is sustained. Moderate dose inhaled corticosteroids (ICS) can typically be reduced,
but questions remain about the lowest effective ICS dose and the role of non-ICS controllers in
treatment reduction. Long acting beta agonist (LABA) safety concerns have created controversy
about how to step down patients on ICS/LABA therapy. This review will focus on the current
status of these issues.
Recent findings—Intermittent ICS treatment, often in fixed combination with short-acting beta
agonist, is an emerging strategy for control of mild asthma. Addition of leukotriene modifiers,
LABAs, and omalizumab to ICS can allow for reduced ICS dosing. Doses of ICS that control
symptoms may be inadequate to control exacerbations. Reducing ICS dose before discontinuing
LABAs may be the more effective approach for patients on combination therapy.
Summary—Use of non-ICS controllers allow for ICS dose reduction with superior outcomes.
Tapering of ICS prior to LABA discontinuation may be the favored approach for patients on ICS/
LABA therapy, but an understanding of long-term outcomes and further safety data are required.
The lowest ICS dose that adequately controls both asthma impairment and risk remains to be
determined.
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Introduction: why consider reducing asthma treatment?
Asthma guidelines focus on achieving and maintaining asthma control and balancing the
risk of medications with control of disease (1, 2). They suggest that once symptoms are
controlled for at least 3 months, therapy can be reduced to the lowest dose that maintains
control. Despite these recommendations, questions remain about when and how to reduce
asthma therapy. Benefits of inhaled corticosteroids (ICS) are well established, and adverse
effects are uncommon at low and moderate doses (3). However, concerns about adverse
effects remain, particularly with sustained high doses, and include osteoporosis, adrenal axis
suppression, cataracts, hoarseness, dysphonia, oral candidiasis, and dermal thinning and
bruising. Recent links of ICS to diabetes and pneumonia are cause for concern and require
further investigation (**4–6). HIV patients on antiretroviral therapy and ICS can have
significant systemic absorption and adverse effects (7). Ongoing concerns in children
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include continued evidence of reduced growth velocity without an ultimate impact on adult
height (8, **9). Apart from concerns about adverse effects of higher doses of ICS, safety
concerns about long acting beta agonists (LABAs) create questions about the optimal way to
reduce combination ICS/LABA therapy (10). Carefully monitored therapy reduction trials
can clarify disease severity and reduce over-treatment. This review will discuss the current
state of knowledge of how one should reduce therapy when asthma control is sustained.
Can daily low dose ICS be reduced or stopped in mild to moderate
persistent asthma?
Once on low dose therapy, the risk of adverse effects of ICS is low (3, 4, 11, 12). However,
patients and some providers still have doubts about ICS safety, leading to the desire to
reduce or stop these medications (13, 14). When mild asthma is controlled, ICS can often be
reduced by 50%, but reducing therapy is less successful with rapid medication tapering and
in moderate to severe disease (15–18). Roughly 50% of children and adults will redevelop
symptoms within 1–12 months if ICS is stopped. (16–19). Seasonal effects are noted, with
greater success weaning in spring and summer, and more failure in the fall (20). In adults
with persistent asthma, the ability to achieve sustained discontinuation of ICS with good
control is rare. (21).
More recently, the utility of biomarkers such as sputum eosinophilia (22, 23), exhaled nitric
oxide (24, 25) and suppression of bronchial hyperreactivity (BHR) (26, 27) have been
considered as tools to guide step-down of asthma therapy. Results are inconclusive, and
even the best studied of these approaches, the fraction of exhaled nitric oxide (FeNO),
cannot consistently predict which patients tolerate reduced therapy (**28). Sputum
eosinophilia has fared the best as a biomarker of loss of control, but access to biomarker
monitoring is not widely available in primary care settings where most mild to moderate
asthmatics receive their care (28).
The use of ICS on an “as needed” basis either alone or paired in the same inhaler with a
short acting beta agonist may minimize ICS exposure. Step-down from daily ICS to
symptom-driven use of fixed dose combination ICS (beclomethasone) and short-acting beta
agonist (SABA) was as effective with a lower ICS dose over 6 months compared to daily
ICS (29). Questions remain: will this strategy remain effective over time? In the TREXA
study, 288 children ages 5–18 stabilized on 80 mcg beclomethasone daily, were stepped
down to either daily ICS + additional rescue ICS as needed, daily ICS alone, rescue ICS
alone, or placebo in a 44 week study. Exacerbations were lower in the daily ICS (28%, 18–
40, p=0.03), combined (31%, 21–43, p=0.07), and rescue (35%, 24–47, p=0.07) groups
compared to placebo (49%)(9). Treatment failure occurred in 23% (95% CI 14–43) of the
placebo group, compared with 5.6% (1.6–14) in the combined (p=0.012), 2.8% (0–10) daily
(p=0.009), and 8.5% (2–15) in the rescue (p=0.024) groups. Overall daily therapy had the
best outcomes but rescue therapy was better than placebo and may reflect real world patient
behavior (30).
In summary, reduction of ICS dose is often successful in well-controlled mild asthma. Long-
term cessation of ICS can be achieved at times in children, but is rarely successful in adults.
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Few biomarkers accurately determine which patients can have therapy reduced and these
techniques are often not available in many practice settings. Approaches using low dose ICS
plus additional as-needed ICS, or as-needed ICS/SABA combination require further study.
Stepping down ICS with use of non ICS anti-inflammatory controllers
When escalating therapy in uncontrolled asthma, addition of non-steroid agents is favored
over increasing to high dose ICS for most patients (1, 2). Less data is available to suggest
that this approach “works in reverse”-that lowering ICS prior to removing non-steroid drugs
is effective at sustaining asthma control. Recent systematic reviews reinforce that LABAs
are effective at controlling asthma with lower ICS doses (31). Leukotriene modifiers (LTM)
are effective as add-on therapy in asthma not controlled on low-dose ICS, but not as
effective as LABAs in adults and possibly children (32, 33). LTM may allow treatment
reduction, but complete cessation of ICS with step-down to LTM or LABA alone is
associated with a significant loss of asthma control compared to maintenance of ICS (34–
36).
There is ample data documenting that omalizumab (anti-IgE) allows reduced ICS dosing. A
2011 systematic review including eight trials and 3429 patients found that omalizumab
treated patients were able to reduce their ICS by 50% or discontinue it entirely (*37). In the
ICATA study, inner city children with moderate to severe asthma treated with omalizumab
plus guidelines-based treatment experienced a 30–48% reduction in exacerbations, including
elimination of seasonal peaks, and better control on less ICS and LABA use (*38). While
perhaps justified in moderate to severe disease, enthusiasm for this approach must by
tempered by the fact that omalizumab has an average wholesale price of $4000-$20000 per
year (39). Given that risk of clinically significant long term side effects of low to moderate
dose ICS are low, and the modest median ICS dose reduction observed in pooled
omalizumab data (median reduced ICS=141 ug budesonide), use of an expensive, resource
intensive medication to taper ICS beyond low to moderate dose may not be warranted.
Stepping down fixed dose combination therapy: reduce ICS or stop LABA?
One of the most common dilemmas currently faced by practicing physicians is how to
reduce ICS/LABA once asthma is controlled. Guidelines recommend a two-step approach:
reducing the ICS by 50% and maintaining the LABA, and stopping the LABA if control is
sustained with low dose ICS (2). In February 2010, in the context of ongoing debates about
LABA safety, the U.S. Food and Drug Administration recommended that LABAs be used
for the shortest duration of time required to control asthma and that LABA therapy should
be discontinued if possible once asthma control is achieved (40). Regulatory agencies
worldwide have not issued a similar recommendation (41). This recommendation has been
interpreted to suggest that LABA should preferentially be discontinued prior to lowering
ICS, which is in conflict with at least some guidelines (2). To date, some limited data is
available comparing these two methods of reducing fixed dose combination therapy, and
published studies on this issue are outlined in Table 1.
Reducing ICS dose prior to discontinuing LABAs is supported by several early studies
where the addition of LABA to ICS allowed a reduction in ICS dose without loss of asthma
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control (18, 35, 42). Steroid naïve patients with moderate persistent asthma controlled on
Fluticasone/ Salmeterol (FSC) 250/50 2x daily were randomized to a 12-week step-down
comparing Fluticasone (FP) 250 2x daily vs. FSC 100/50 2 x daily (43). Peak expiratory
flow (PEF), the primary endpoint, was maintained in the FSC100/50 group but decreased
slightly in FP group. The proportion of patients with well-controlled asthma, a secondary
endpoint, was reduced in both groups compared to 250/50, but remained higher in FSC vs.
FP. More recently, patients uncontrolled on low dose ICS but controlled on FSC 100/50 for
4 weeks, were either continued on FSC, or stepped down to either same dose FP alone (100
mcg), salmeterol alone (50 mcg), or montelukast alone. FSC was superior for all endpoints
(morning PEF, FEV1, symptom scores, and likelihood of remaining in the study) (36).
Similarly, in a 6 month trial of patients well-controlled on FSC 250/50 2x daily who were
stepped down to FSC 100/50 or FP 250 2x daily, FSC 100/50 was better than FP at
maintaining lung function and symptom control (44). FSC 100/50 was non-inferior to
continuing FSC 250. The withdrawal rate in the FP group (20%) was double that of either
FSC 250 (11%) or FSC 100 (9%). Recently, Reddel et al stepped down patients from FSC
500 2x daily to either FP 500 2x daily or progressively lower dose FSC at 8-week intervals.
No difference was found in the primary endpoint (mean FP dose), but the FSC group
achieved a lower final ICS dose than the FP group (*45). Finally, in a complex retrospective
study of a large managed care claims database, patients stepped down from higher to lower
dose FSC compared to FP alone had less SABA use (30%, 1.72 vs. 2.48, p=0.001), 26%
lower risk of systemic corticosteroid use (24% vs. 32%, p=0.006), 48% lower risk of an
asthma-related hospitalization or ED visit (3.8% vs. 7.4%, p=0.01), and higher refill
persistence rates compared with FP (*46). Although data so far suggest improved outcomes
maintaining LABA during step-down, given the short step-down phases in most studies (12–
24 weeks) and use of primary outcomes such as PEF rather than composite measures of
control or exacerbation rates, a definitive answer awaits further study. Efficacy studies such
as these are always underpowered to address the issue of LABA safety, a critical issue in
weighing risks vs. benefits of asthma therapies. A best estimate of the risk of adverse effects
of LABA is important, is an area of significant controversy that may or may not be clarified
with upcoming U.S. FDA mandated LABA safety mega-trial (47).
More recent trials of adjustable and maintenance dosing of combination Budesonide and
Formoterol (Bud/Form) suggest that adjustable vs. fixed therapy may be associated with
equal symptom control at lower ICS doses (48). In a complex study that simultaneously
compared the effects of lowering ICS, removing LABA, and once vs. twice daily ICS
dosing, twice-daily Bud/Form generally fared better than once daily ICS or ICS/LABA.
Combination therapy once or twice daily fared better than ICS alone (49). Enthusiasm for
this approach has been somewhat hampered by LABA safety concerns, although a recent
meta-analysis did not show an increased risk of adverse events compared with fixed dosing
of ICS/LABA (50). Further studies of adjustable and maintenance dosing of Bud/Form as a
means of reducing medication once asthma is controlled seem warranted.
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Is stepping down beyond moderate dose ICS in adults and low dose ICS in
children necessary?
Once asthma control is achieved and sustained, how low should the ICS dose be reduced?
Low and moderate dose ICS do not differ in terms of symptom control, but moderate dose
ICS may have a slight advantage in terms of lung function (FEV1 in adults but not children)
and at reducing exacerbations (51). Good data suggests that the long-term safety profile of
low to moderate dose ICS is favorable (3, 12, 52). In adults with persistent asthma,
continuation of moderate dose (FSC 250) ICS/LABA resulted in marginally better symptom
control and lung function compared to adjustable and maintenance Bud/Fom, but a striking
50% lower exacerbation rate (53). At the end of one year, both groups ended up on just
under 500ug daily of either FP or Bud, respectively. This study suggests that patient-dictated
adjustment of medication according to symptoms slightly lowers ICS exposure, but possibly
at the cost of a higher exacerbation rate. It also suggests that there is a minimum daily ICS
dose needed to prevent exacerbations, at least in adults. The suggestion has been made to
use low dose ICS and then increase ICS at the first signs of an exacerbation. Data evaluating
this approach show that doubling ICS does not prevent exacerbations (54). It seems that
once control is lost, it may not be easily regained. These findings highlight the critical need
for long-term step-down studies in both children and adults. If the tradeoff of reduced ICS
results in additional exacerbations per year, any benefit gained by ICS reduction may be
offset by greater exposure to systemic steroids. In adults, where asthma remission is
uncommon, and co-morbid conditions abound, the addition of even one extra course of oral
steroids per year over many years may carry more risk of adverse events than maintenance
of moderate-dose ICS. In terms of risk of accelerated decline of lung function, prevention by
ICS is currently not supported by data and further study is needed (11, 55). A key study
would be a long term study along the lines of the Childhood Asthma Management Program
study, including both children and adults and comparing reducing ICS vs. maintaining stable
dosing and evaluating long term outcomes and adverse effects (11).
Conclusion
Although step-down of controller medication to the lowest dose which controls asthma is an
appropriate goal, many unanswered questions remain regarding how to best accomplish this,
and what the ultimate “lowest” dose should be. Current recommendations for step-down of
therapy do not account for the heterogeneity of asthma, do not make clear distinctions based
on disease severity, and do not sufficiently incorporate consideration of disease risk. Current
data is overrepresented with short-term studies that may underestimate risk of exacerbations
on lower medication dosing and may overstate the benefits of lower dosing compared to
risks. More data is needed regarding the ideal duration of control prior to tapering, and the
best approach to stepping down patients with severe asthma, particularly those on moderate
to high dose ICS/LABA. It is unclear if the outcomes of clinical trials, where patients
undergo careful monitoring, is representative of outcomes that can be achieved in general
practice settings. Pragmatic clinical trials that recreate typical practice may be needed for
better answers.
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Bud/Form Budesonide/Formoterol combination inhaler
FeNO fraction of exhaled nitric oxide
FEV1 forced exhaled volume in 1 second
FP Fluticasone propionate inhaler
FSC Fluticasone/Salmeterol combination inhaler
ICATA Inner City Anti-IgE Therapy for Treating Asthma Mechanistic Study
ICS inhaled corticosteroids
LABA long acting beta-agonist
LTM leukotriene modifier
PEF peak expiratory flow rate
SABA short-acting beta-agonist
TREXA Treating Children to Prevent Exacerbations Study
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